#Switzerland #Zurich #IsletRx #NewCelX #Dr. Julien Boisdron

NewcelX Welcomes Dr. Julien Boisdron to Scientific Advisory Board

In a significant move to enhance its research capabilities, NewcelX Ltd. has appointed Dr. Julien Boisdron, a well-regarded leader in diabetes innovation, to its Scientific Advisory Board (SAB). This announcement, made on January 5, 2026, reflects NewcelX's commitment to advancing therapies for diabetes, especially insulin-dependent Type 1 Diabetes.

Dr. Boisdron is not just any medical professional; he has carved a niche for himself over two decades in the competitive landscape of diabetes care, particularly within the Swiss pharmaceutical sector. Currently serving as the Chief Medical Officer for a major multinational pharmaceutical company, Dr. Boisdron is pivotal in shaping clinical programs and strategies related to next-generation diabetes technologies. His expertise ranges from connected-care innovation to the formulation of advanced insulin-management systems, making him an invaluable asset to NewcelX.

As a member of the SAB, Dr. Boisdron will provide critical insights and strategic guidance as the company progresses its lead therapeutic program, IsletRx. This innovative treatment aims to address the challenges faced by patients with insulin-dependent Type 1 Diabetes through stem-cell-derived islet cell therapy.

Despite being in its early stages, IsletRx represents NewcelX's primary focus and a major component of its clinical development strategy. Dr. Boisdron's involvement is expected to steer the translational strategy forward, ensuring that as clinical trials commence, patient-adoption considerations, health-system integration, and global commercialization frameworks are thoroughly addressed.

"I am honored to join NewcelX's Scientific Advisory Board and to collaborate on advancing next-generation therapies for diabetes," remarked Dr. Boisdron. He emphasized the promising potential of NewcelX's integrated platform, which merges cell-therapy with neuroscience innovation. Such a foundation, according to Dr. Boisdron, is vital for pushing transformative treatments closer to patients who need them.

In response to this strategic appointment, Prof. Michel Revel, Chief Scientific Officer of NewcelX, stated that bringing Dr. Boisdron onboard fortifies the company’s leadership in both metabolic and regenerative medicine domains. His experience in diabetes care and global medical leadership is anticipated to greatly enrich the company's strategic direction, particularly for the ongoing IsletRx initiative.

Ronen Twito, the Executive Chairman and CEO of NewcelX, highlighted Dr. Boisdron's significance within the framework of their clinical development strategy, especially with Type 1 Diabetes being the core focus. His rich expertise in diabetes innovation and understanding of clinical strategy across different healthcare systems will play a crucial role in embracing a patient-centered approach to developing their cell-based therapy.

About NewcelX Ltd.

NewcelX Ltd., traded on Nasdaq under the ticker NCEL, is focused on developing impactful cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company combines advanced stem-cell technologies with neuroscience expertise to offer scalable, regenerative treatments targeting serious conditions like ALS and Type 1 Diabetes. Based in Zurich, Switzerland, with research facilities in Ness Ziona, Israel, NewcelX is positioned to be a frontrunner in the biotechnology sector, spurred by innovations stemming from its robust advisory board and dedicated team.

As NewcelX continues its trajectory towards clinical trials for IsletRx and beyond, the inclusion of Dr. Boisdron marks a key step in strengthening the company's leadership and strategic vision in tackling some of the most challenging health issues faced today.